Eledon Advances Tegoprubart In Islet Cell And Kidney Transplant Programs

Eledon Pharmaceuticals, Inc. (ELDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Lo

NewcelX (Nasdaq: NCEL) said it completed a Type B Pre-IND meeting with the FDA for NCEL-101 in type 1 diabetes, with FDA feedback aligning on a regulatory path toward IND-enabling activities and a planned clinical trial. The trial would combine NCEL-101 with Eledon Pharmaceuticals’ (Nasdaq: ELDN) tegoprubart (anti-CD40L).

Eledon Pharmaceuticals (ELDN) reported updated investigator-initiated trial results for tegoprubart, an anti-CD40L antibody, in type 1 diabetes patients receiving allogeneic islet cell transplants at the University of Chicago. According to the company, all 12 patients achieved insulin independence, with mean most recent HbA1c ~5.4% and stable graft function over a median 8 months (max 22). No rejection or de novo donor-specific HLA antibodies were reported. Eledon said it will seek FDA regulator

CME Group plans to launch AI compute futures contracts on October 5, 2026, pending approval. These contracts will provide a market price for AI compute resources, benefiting Bitcoin miners who are diversifying into AI data centers. The contracts are based on Silicon Data's index of Nvidia GPUs, with rental rates around $5.86/hour for B200 and $2.77/hour for H100. The AI compute market is projected to grow significantly, with volatility driving demand for hedging.

Synopsys (SNPS) announced multi-year AI collaborations with OpenAI and Amazon, boosting its stock by 4.8%. The company's share price has surged 17.77% over 30 days. Analysts estimate its fair value at $545.93, citing strong growth potential from AI and the integration of Ansys. However, its high P/E ratio of 87.2x raises valuation concerns.

Uniswap is collaborating with SMBC Nikko, Nethermind, Base, and Nyx Foundation to develop a Japan-focused DeFi Gateway, targeting mid-2027 completion. The project aims to create compliant liquidity pools using Uniswap v4 hooks. Uniswap reported $14.7 million in September revenue, with 53% from Robinhood Chain. UNI price is consolidating, with a potential breakout from a falling wedge pattern.